Efficacy of Rituximab for Refractory Pyoderma Gangrenosum-Like Ulcers in Granulomatosis With Polyangiitis Associated to Antiphospholipid Antibodies

Julia RIERA, Jorge MUSURUANA, Cecilia COSTA, Javier CAVALLASCA

Hospital JB Iturraspe, Rheumatology and Autoimmune Diseases, Santa Fe, Argentina

Keywords: Antiphospholipid antibodies, granulomatosis with polyangiitis, pyoderma gangrenosum, rituximab

Abstract

Pyoderma gangrenosum (PG) is a neutrophilic dermatosis that most often presents with painful ulcerations of violaceous borders in lower limbs and/or trunk. PG treatment varies according to the severity of the lesion and may either respond to local therapies or require immunosuppressive agents. In this article, we present the case of an antiphospholipid antibody-positive 59-year-old female patient diagnosed with granulomatosis with polyangiitis who developed severe PG-like skin involvement that was responsive to rituximab therapy.

Citation: Riera J, Musuruana J, Costa C, Cavallasca J. Efficacy of Rituximab for Refractory Pyoderma Gangrenosum-Like Ulcers in Granulomatosis With Polyangiitis Associated to Antiphospholipid Antibodies. Arch Rheumatol 2020;35(3):449-453.

Conflict of Interest

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Financial Disclosure

The authors received no financial support for the research and/or authorship of this article.